Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder.

Michel Alexander Steiner Luca BotticelliGiorgio BergaminiEmanuela Micioni Di BonaventuraJohn GatfieldJodi T WilliamsAlexander TreiberCatherine VaillantCarlo Cifani Maria Vittoria Micioni Di Bonaventura

Published in: The International journal of eating disorders (2024)

Nivasorexant is a new investigational drug for the treatment of binge-eating disorder (BED). It underwent clinical testing in a phase II proof of concept trial in humans but was not efficacious compared with placebo. The current manuscript investigated the drug's efficacy in reducing binge-like eating behavior of a highly palatable sweet and fat diet in a rat model of BED, which initially laid the foundation for the clinical trial.

Keyphrases

phase ii
clinical trial
phase iii
open label
double blind
placebo controlled
physical activity
weight loss
study protocol
adipose tissue
adverse drug
randomized controlled trial
drug induced
atomic force microscopy
emergency department
combination therapy
high resolution